Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818304 | 1.00 | PPARA (0.62) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL8162953 | 0.90 | PPARA (0.67) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL17492179 | 0.89 | NFKB1 (0.52) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL17492177 | 0.89 | NFKB1 (0.52) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL3109195 | 0.88 | PPARA (0.51) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL3763496 | 0.88 | ITGB3 (0.54) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL17491991 | 0.88 | ITGB3 (0.54) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL345468 | 0.88 | ITGB3 (0.54) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL4816376 | 0.88 | ITGB3 (0.54) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL17492215 | 0.88 | PPARA (0.57) | PPARAPPARGACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119677716-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | VIVIDION THERAPEUTICS, INC. | 2025-01-07 | — | — | US | disclosed |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024010782-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-106459147-B | Serine derivatives as ghrelin receptor agonists | 拉夸里亚创药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| EP-3131916-B1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-9873695-B2 | Serine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3131916-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc (JP) | 2017-02-22 | — | — | EP | disclosed |
| CN-106459147-A | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | 拉夸里亚创药株式会社 | 2017-02-22 | — | — | CN | disclosed |
| WO-2016021191-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | PPARA 911/4885PPARG 345/4885ACE 2198/4885 |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | PPARA 3369/4885PPARG 3244/4885ACE 1765/4885 |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | PPARA 3369/4885PPARG 3244/4885ACE 1765/4885 |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | RECQL, BLM, WRN | PPARA 3369/4885PPARG 3244/4885ACE 1765/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | PPARA 3369/4885PPARG 3244/4885ACE 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.